Authors: Nguyen, H.P., An, K., Ito, Y. et al.
Source: Nature Biotechnology (2025).
We are thrilled to share insights from a genuine study entitled "Implantation of engineered adipocytes suppresses tumor progression in cancer models" published in Nature Biotechnology by Hai P. Nguyen et al:
"Tumors exhibit an increased ability to obtain and metabolize nutrients. Here, we implant engineered adipocytes that outcompete tumors for nutrients and show that they can substantially reduce cancer progression, a technology termed adipose manipulation transplantation (AMT). Adipocytes engineered to use increased amounts of glucose and fatty acids by upregulating UCP1 were placed alongside cancer cells or xenografts, leading to significant cancer suppression. Transplanting modulated adipose organoids in pancreatic or breast cancer genetic mouse models suppressed their growth and decreased angiogenesis and hypoxia. Co-culturing patient-derived engineered adipocytes with tumor organoids from dissected human breast cancers significantly suppressed cancer progression and proliferation. In addition, cancer growth was impaired by inducing engineered adipose organoids to outcompete tumors using tetracycline or placing them in an integrated cell-scaffold delivery platform and implanting them next to the tumor. Finally, we show that upregulating UPP1 in adipose organoids can outcompete a uridine-dependent pancreatic ductal adenocarcinoma for uridine and suppress its growth, demonstrating the potential customization of AMT."
Congratulations to all authors for this great article.
Our CombiMag was used for CRISPR/Cas9 Genome edition, by transfecting DNA plasmids in human preadipocytes and mouse 3T3-L1.
Our AdenoMag was used for CRISPR/Cas9 Genome modification, in adipocytes with AAV9.
Read the article See our CombiMag See our AdenoMag
Related publications
MARCH1 inhibits GABAB receptor recycling under ischemic conditions
TRACERx analysis identifies a role for FAT1 in regulating chromosomal
